JP2016501843A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501843A5
JP2016501843A5 JP2015540216A JP2015540216A JP2016501843A5 JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5 JP 2015540216 A JP2015540216 A JP 2015540216A JP 2015540216 A JP2015540216 A JP 2015540216A JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
lymphoma
fragments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501843A (ja
Filing date
Publication date
Priority claimed from GBGB1220010.1A external-priority patent/GB201220010D0/en
Application filed filed Critical
Publication of JP2016501843A publication Critical patent/JP2016501843A/ja
Publication of JP2016501843A5 publication Critical patent/JP2016501843A5/ja
Pending legal-status Critical Current

Links

JP2015540216A 2012-11-07 2013-11-06 癌治療および判断ターゲットとしてのly75 Pending JP2016501843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1220010.1 2012-11-07
GBGB1220010.1A GB201220010D0 (en) 2012-11-07 2012-11-07 Therapeutic amd diagnostic target
PCT/GB2013/052899 WO2014072700A1 (en) 2012-11-07 2013-11-06 Ly75 as cancer therapeutic and diagnostic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018141190A Division JP7079685B2 (ja) 2012-11-07 2018-07-27 癌治療および判断ターゲットとしてのly75

Publications (2)

Publication Number Publication Date
JP2016501843A JP2016501843A (ja) 2016-01-21
JP2016501843A5 true JP2016501843A5 (https=) 2016-11-24

Family

ID=47429281

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015540216A Pending JP2016501843A (ja) 2012-11-07 2013-11-06 癌治療および判断ターゲットとしてのly75
JP2018141190A Active JP7079685B2 (ja) 2012-11-07 2018-07-27 癌治療および判断ターゲットとしてのly75
JP2020154083A Pending JP2021011483A (ja) 2012-11-07 2020-09-14 癌治療および判断ターゲットとしてのly75
JP2022177986A Active JP7479435B2 (ja) 2012-11-07 2022-11-07 癌治療および判断ターゲットとしてのly75

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018141190A Active JP7079685B2 (ja) 2012-11-07 2018-07-27 癌治療および判断ターゲットとしてのly75
JP2020154083A Pending JP2021011483A (ja) 2012-11-07 2020-09-14 癌治療および判断ターゲットとしてのly75
JP2022177986A Active JP7479435B2 (ja) 2012-11-07 2022-11-07 癌治療および判断ターゲットとしてのly75

Country Status (15)

Country Link
US (3) US20150297743A1 (https=)
EP (1) EP2917239A1 (https=)
JP (4) JP2016501843A (https=)
KR (1) KR102256552B1 (https=)
CN (2) CN113181372A (https=)
AU (2) AU2013343277B2 (https=)
BR (1) BR112015009438B1 (https=)
CL (1) CL2015001098A1 (https=)
EA (1) EA033649B1 (https=)
GB (1) GB201220010D0 (https=)
HK (1) HK1214611A1 (https=)
NZ (1) NZ707116A (https=)
SG (2) SG11201503363WA (https=)
UA (1) UA117569C2 (https=)
WO (1) WO2014072700A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
SI3055331T1 (sl) * 2013-10-11 2021-04-30 Oxford Bio Therapeutics Limited Konjugirana protitelesa proti LY75 za zdravljenje raka
US10260109B2 (en) 2015-05-29 2019-04-16 Universiteit Maastricht Method for identifying subjects with aggressive melanoma skin cancer at diagnosis
KR101796091B1 (ko) 2016-05-02 2017-11-10 충남대학교 산학협력단 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN109685135B (zh) * 2018-12-21 2022-03-25 电子科技大学 一种基于改进型度量学习的少样本图像分类方法
CA3162518A1 (en) * 2019-11-26 2021-06-03 Cedars-Sinai Medical Center Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
JPWO2023032996A1 (https=) 2021-08-31 2023-03-09
EP4397672A4 (en) 2021-08-31 2025-02-26 FUJIFILM Corporation Compound and labeled biomaterial using same
CN117642413A (zh) 2021-08-31 2024-03-01 富士胶片株式会社 化合物及使用了该化合物的标记生物物质
MX2024003132A (es) * 2021-09-13 2024-04-10 Regeneron Pharma Metodos para tratar la hematopoyesis clonal de potencial indeterminado (chip) con inhibidores del antigeno linfocitario 75 (ly75), grupo de diferenciacion 164 (cd164) o poli (adp-ribosa) polimerasa 1 (parp1).
EP4644874A1 (en) 2022-12-26 2025-11-05 FUJIFILM Corporation Fluorescence intensity enhancing agent, method for enhancing fluorescence intensity of fluorescently labeled target biological material, and fluorescence detection kit
WO2024181454A1 (ja) 2023-02-27 2024-09-06 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
CN120752249A (zh) 2023-02-27 2025-10-03 富士胶片株式会社 化合物及使用了该化合物的标记生物物质
WO2025047686A1 (ja) 2023-08-31 2025-03-06 富士フイルム株式会社 標的化薬物複合体及びこれを含む医薬、並びに、化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
EP1015489B1 (en) * 1996-05-29 2006-07-05 Derek Nigel John Hart Dendritic cell receptor
EP1370292A1 (en) * 2001-01-31 2003-12-17 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
JP2010529966A (ja) * 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてmiR−34によって調節される遺伝子および経路
NZ599777A (en) * 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2159291A1 (en) * 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
WO2011044452A2 (en) * 2009-10-08 2011-04-14 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
JP6431104B2 (ja) * 2017-02-27 2018-11-28 オリコン株式会社 マイクロ波を利用した金属蒸気の発生方法

Similar Documents

Publication Publication Date Title
JP2016501843A5 (https=)
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
RU2017132214A (ru) Анти-pvrig антитела и способы применения
Rebouissou et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro
JP2016513094A5 (https=)
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
JP2010518847A5 (https=)
JP2011509079A5 (https=)
JP2016500110A5 (https=)
EA201691144A1 (ru) Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
JP2017501137A5 (https=)
JP2017518366A5 (https=)
JP2014530877A5 (https=)
JP2008538289A5 (https=)
JP2014513068A5 (https=)
JP2009536834A5 (https=)
RU2018125490A (ru) Нейтрализация ингибиторных путей в лимфоцитах
RU2014140119A (ru) Способы повышения эффективности терапии на основе cd37
JP2015514716A5 (https=)
US20150361504A1 (en) Biomarker for predicting response of cll to treatment with a btk inhibitor
JP2010535506A5 (https=)
JP2015523852A5 (https=)
Afonso et al. QCM immunoassay for recombinant cysteine peptidase: A potential protein biomarker for diagnosis of citrus canker
RU2011131071A (ru) Диагностика и лечение рака с помощью антитела против lgr7